CAS No.:64953-12-4

TOXICITY DATA with REFERENCE：

1.		orl-man TDLo:571 mg/kg/20D-I:GIT		JAMAAP    JAMA, Journal of the American Medical Association. 250 (1983),730.
2.		ivn-man LDLo:371 mg/kg/17D-I:BLD		DICPBB    Drug Intelligence and Clinical Pharmacy. 18 (1984),140.
3.		ivn-man TDLo:1143 mg/kg/10D-I:BLD		DICPBB    Drug Intelligence and Clinical Pharmacy. 18 (1984),721.
4.		ipr-rat LD50:8100 mg/kg		NIIRDN    Drugs in Japan. Ethical Drugs, 6th Edition 1982 6 (1982),APP-21.
5.		scu-rat LD50:9000 mg/kg		NIIRDN    Drugs in Japan. Ethical Drugs, 6th Edition 1982 6 (1982),APP-21.
6.		ivn-rat LD50:5500 mg/kg		NIIRDN    Drugs in Japan. Ethical Drugs, 6th Edition 1982 6 (1982),APP-21.
7.		ipr-mus LD50:8100 mg/kg		NIIRDN    Drugs in Japan. Ethical Drugs, 6th Edition 1982 6 (1982),APP-21.
8.		scu-mus LD50:9000 mg/kg		NIIRDN    Drugs in Japan. Ethical Drugs, 6th Edition 1982 6 (1982),APP-21.
9.		ivn-mus LD50:5500 mg/kg		NIIRDN    Drugs in Japan. Ethical Drugs, 6th Edition 1982 6 (1982),APP-21.

Consensus Reports：

 

SAFETY PROFILE：

Mildly toxic by several routes. An experimental teratogen. Other experimental reproductive effects. Human systemic effects: ulceration or bleeding from small and large intestine, hemorrhage, thrombocytopenia. When heated to decomposition it emits toxic fumes of SO_x, NO_x, and Na₂O.
Hazard Codes:
Xn: Harmful
Risk Statements about Latamoxef sodium (64953-12-4):
R42/43: May cause sensitization by inhalation and skin contact.
Safety Statements about Latamoxef sodium (64953-12-4):
S22 Do not breathe dust.
S45 In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
S36/37: Wear suitable protective clothing and gloves.

Standards and Recommendations：

 

Analytical Methods：